Table 4: Details in patients pre-treated with pertuzumab.
Number of patients (%) | ||
Total | 41 | |
Number of previous regimens for metastatic breast cancer | ||
0 | 0 | |
1 | 11 (27%) | |
2 | 5 (12%) | |
3 | 6 (15%) | |
≥ 4 | 19 (46%) | |
Response to T-DM1 | ||
Complete response | 2 (5%) | |
Partial response | 10 (24%) | |
Long stable disease (≥ 6 months) | 7 (17%) | |
Stable disease (< 6 months) | 6 (15%) | |
Progressive disease | 14 (34%) | |
Not evaluable | 2 (5%) | |
Response rate | 29% | |
Clinical benefit rate | 46% | |
Median time to treatment failure, months (range) | 5.0 (0.7-21.0) | |
Adverse events (Grade 3/4) | ||
Thrombocytopenia | 9 (22%) | |
Increased ALT and/or AST | 3 (7%) | |
Rash | 0 | |
Neutropenia | 1 (2%) |